Institute of Pathology, Molecular Pathology, University of Regensburg, Regensburg, Germany.
Clin Biochem. 2013 Jul;46(10-11):909-17. doi: 10.1016/j.clinbiochem.2013.01.008. Epub 2013 Jan 27.
Melanoma is the most aggressive form of skin cancer, and the incidence of melanoma has been increasing faster than that of most other cancers. While the survival rate following surgical resection of early-stage primary tumors is nearly 100%, the survival of patients with metastasized tumors is strongly reduced, likely due to resistance to conventional therapies. Therefore, it is important to use new molecular approaches to develop new biomarkers to better prevent and diagnose melanoma. MicroRNAs (miRNAs) are short non-coding RNAs that post-transcriptionally regulate gene expression via repression of translation or direct degradation of their complementary mRNA. In this review, we summarize our current understanding of the involvement of miRNAs and their corresponding targets in melanomagenesis as well as the potential use of miRNAs as biomarkers.
黑色素瘤是最具侵袭性的皮肤癌,其发病率的增长速度比大多数其他癌症都要快。虽然早期原发性肿瘤手术切除后的存活率接近 100%,但转移性肿瘤患者的存活率却大大降低,这可能是由于对常规疗法产生了耐药性。因此,利用新的分子方法开发新的生物标志物来更好地预防和诊断黑色素瘤非常重要。微小 RNA(miRNA)是一类短的非编码 RNA,通过抑制翻译或直接降解与其互补的 mRNA 来实现转录后基因表达调控。在这篇综述中,我们总结了 miRNA 及其相应靶基因在黑色素瘤发生中的作用,以及 miRNA 作为生物标志物的潜在用途。